Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 184 HER2-positive Breast Cancer 18 Neoplasms 13 Neoplasm Metastasis 11 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Pancreatic Neoplasms 5 Inflammatory Breast Neoplasms 5 Colonic Neoplasms 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Multiple Myeloma 4 Hematologic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Urinary Bladder Neoplasms 3 Solid Tumor 3 Rectal Neoplasms 3 Pathologic Complete Response 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 HER2-positive Early Breast Cancer 3 Esophageal Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Salivary Gland Neoplasms 2 Locally Advanced Breast Cancer 2

Interventions

pertuzumab 1 Vemurafenib 1 Trastuzumab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Feasibility × pertuzumab × Clear all

NCT05177666 2022-01-04

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

The University of Hong Kong-Shenzhen Hospital

Feasibility

Data powered by HemOnc (CC BY 4.0) Colophon ⚡